241 related articles for article (PubMed ID: 28566368)
21. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
22. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
23. Aspergillus fumigatus Transcription Factors Involved in the Caspofungin Paradoxical Effect.
Valero C; Colabardini AC; Chiaratto J; Pardeshi L; de Castro PA; Ferreira Filho JA; Silva LP; Rocha MC; Malavazi I; Costa JH; Fill T; Barros MH; Wong SSW; Aimanianda V; Wong KH; Goldman GH
mBio; 2020 Jun; 11(3):. PubMed ID: 32546620
[No Abstract] [Full Text] [Related]
24. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.
Hohl TM; Feldmesser M; Perlin DS; Pamer EG
J Infect Dis; 2008 Jul; 198(2):176-85. PubMed ID: 18500928
[TBL] [Abstract][Full Text] [Related]
25. [Case of chronic necrotizing pulmonary aspergillosis complicated by elevated eosinophils and serum IgE].
Morita H; Oguri T; Uemura T; Iwashima Y; Nakamura A; Sato S
Nihon Kokyuki Gakkai Zasshi; 2010 Nov; 48(11):842-6. PubMed ID: 21141064
[TBL] [Abstract][Full Text] [Related]
26. Caspofungin exposure alters the core septin AspB interactome of Aspergillus fumigatus.
Vargas-Muñiz JM; Renshaw H; Waitt G; Soderblom EJ; Moseley MA; Palmer JM; Juvvadi PR; Keller NP; Steinbach WJ
Biochem Biophys Res Commun; 2017 Apr; 485(2):221-226. PubMed ID: 28238781
[TBL] [Abstract][Full Text] [Related]
27. Scanning Quadrupole Data-Independent Acquisition, Part B: Application to the Analysis of the Calcineurin-Interacting Proteins during Treatment of Aspergillus fumigatus with Azole and Echinocandin Antifungal Drugs.
Juvvadi PR; Moseley MA; Hughes CJ; Soderblom EJ; Lennon S; Perkins SR; Thompson JW; Geromanos SJ; Wildgoose J; Richardson K; Langridge JI; Vissers JPC; Steinbach WJ
J Proteome Res; 2018 Feb; 17(2):780-793. PubMed ID: 29251506
[TBL] [Abstract][Full Text] [Related]
28. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins.
Arendrup MC; Perkhofer S; Howard SJ; Garcia-Effron G; Vishukumar A; Perlin D; Lass-Flörl C
Antimicrob Agents Chemother; 2008 Oct; 52(10):3504-11. PubMed ID: 18644959
[TBL] [Abstract][Full Text] [Related]
29. Echinocandins: the newest class of antifungals.
Sucher AJ; Chahine EB; Balcer HE
Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
[TBL] [Abstract][Full Text] [Related]
30. Voriconazole inhibits fungal growth without impairing antigen presentation or T-cell activation.
Van Epps HL; Feldmesser M; Pamer EG
Antimicrob Agents Chemother; 2003 Jun; 47(6):1818-23. PubMed ID: 12760853
[TBL] [Abstract][Full Text] [Related]
31. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6767-72. PubMed ID: 25182639
[TBL] [Abstract][Full Text] [Related]
32. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
Arendrup MC; Garcia-Effron G; Buzina W; Mortensen KL; Reiter N; Lundin C; Jensen HE; Lass-Flörl C; Perlin DS; Bruun B
Antimicrob Agents Chemother; 2009 Mar; 53(3):1185-93. PubMed ID: 19104024
[TBL] [Abstract][Full Text] [Related]
33. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
Groll AH; Walsh TJ
Expert Opin Investig Drugs; 2001 Aug; 10(8):1545-58. PubMed ID: 11772269
[TBL] [Abstract][Full Text] [Related]
34. [Azole-resistant invasive aspergillosis].
van der Linden JW; Warris A; van der Meer JW; Bresters D; Melchers WJ; Verweij PE
Ned Tijdschr Geneeskd; 2009; 153():A765. PubMed ID: 20051169
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
36. Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in Aspergillus fumigatus.
Lamoth F; Juvvadi PR; Soderblom EJ; Moseley MA; Steinbach WJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4727-33. PubMed ID: 26014950
[TBL] [Abstract][Full Text] [Related]
37. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.
Lockhart SR; Zimbeck AJ; Baddley JW; Marr KA; Andes DR; Walsh TJ; Kauffman CA; Kontoyiannis DP; Ito JI; Pappas PG; Chiller T
Antimicrob Agents Chemother; 2011 Aug; 55(8):3944-6. PubMed ID: 21670187
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
39. The echinocandins: three useful choices or three too many?
Bal AM
Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
[TBL] [Abstract][Full Text] [Related]
40. Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus.
Lamoth F; Juvvadi PR; Soderblom EJ; Moseley MA; Asfaw YG; Steinbach WJ
Antimicrob Agents Chemother; 2014; 58(4):1889-96. PubMed ID: 24395240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
